Biotechnology company UroGen Pharma Ltd (Nasdaq: URGN) announced on Monday that the FDA has accepted the Investigational New Drug (IND) application for UGN-103, a novel mitomycin-based formulation targeting low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Leveraging the RTGel platform technology, UGN-103 aims to streamline production processes and enhance treatment convenience.
Plans include initiating a Phase 3 study in 2024 to evaluate safety and efficacy.
If approved, UGN-103's anticipated advantages include an 80 mg mitomycin dosage strength and potential extended intellectual property protection until December 2041.
The company is dedicated to advancing innovative solutions for urothelial and specialty cancers.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option